<div class="table-wrap table anchored whole_rhythm" id="t3-copd-13-1229">
<h3>Table 3</h3>
<!--caption a7--><div class="caption"><p id="__p45">Effect of IND/GLY on individual outcome measures compared with LABA or LAMA</p></div>
<div data-largeobj="" data-largeobj-link-rid="largeobj_idm139931939280240" class="xtable"><table frame="hsides" rules="groups" class="rendered small default_table">
<thead><tr>
<th rowspan="1" colspan="1" valign="top" align="left">Outcome measures</th>
<th rowspan="1" colspan="1" valign="top" align="left">IND/GLY<sup>a</sup> (n=811)</th>
<th rowspan="1" colspan="1" valign="top" align="left">LABA or LAMA<sup>a</sup> (n=268)</th>
<th rowspan="1" colspan="1" valign="top" align="left">IND/GLY versus LABA or LAMA odds ratio (95% CI)</th>
</tr></thead>
<tbody>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Decrease in trough FEV<sub>1</sub> of ≥100 mL</td>
<td rowspan="1" colspan="1" valign="top" align="left">100 (12.3)</td>
<td rowspan="1" colspan="1" valign="top" align="left">74 (27.6)</td>
<td rowspan="1" colspan="1" valign="top" align="left">0.37 (0.26–0.52)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Decrease in TDI of ≥1 point</td>
<td rowspan="1" colspan="1" valign="top" align="left">72 (8.9)</td>
<td rowspan="1" colspan="1" valign="top" align="left">42 (15.7)</td>
<td rowspan="1" colspan="1" valign="top" align="left">0.55 (0.37–0.83)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Increase in CCQ of ≥0.4 point</td>
<td rowspan="1" colspan="1" valign="top" align="left">93 (11.5)</td>
<td rowspan="1" colspan="1" valign="top" align="left">51 (19.0)</td>
<td rowspan="1" colspan="1" valign="top" align="left">0.55 (0.38–0.81)</td>
</tr>
<tr>
<td rowspan="1" colspan="1" valign="top" align="left">Incidence of AECOPD<sup>b</sup>
</td>
<td rowspan="1" colspan="1" valign="top" align="left">44 (5.4)</td>
<td rowspan="1" colspan="1" valign="top" align="left">19 (7.0)</td>
<td rowspan="1" colspan="1" valign="top" align="left">0.75 (0.43–1.31)</td>
</tr>
</tbody>
</table></div>
<div id="largeobj_idm139931939280240" class="largeobj-link align_right" style="display: none"><a target="object" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5909796/table/t3-copd-13-1229/?report=objectonly">Open in a separate window</a></div>
<div class="tblwrap-foot">
<div id="idm139931931098976"><p id="__p46" class="p p-first-last"><strong>Notes:</strong></p></div>
<div id="tfn5-copd-13-1229">
<sup>a</sup>Patients had mMRC ≥2.</div>
<div id="tfn6-copd-13-1229">
<sup>b</sup>As
 adverse event reporting. Data presented as number and percentage of 
patients with clinically important deterioration, unless otherwise 
specified.</div>
<div id="tfn7-copd-13-1229"><p id="__p49" class="p p-first-last"><strong>Abbreviations:</strong> AECOPD, acute exacerbation of moderate/severe COPD; CCQ, clinical COPD questionnaire; FEV<sub>1</sub>, forced expiratory volume in 1 second; IND/GLY, indacaterol/glycopyrronium; LABA, long-acting β<sub>2</sub>-agonist; LAMA, long-acting muscarinic antagonist; mMRC, modified Medical Research Council; TDI, transition dyspnea index.</p></div>
</div>
</div>